Catalent has launched of its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation development, on-demand clinical manufacturing, regulatory support and clinical testing, the approach can reduce both the cost and time taken to complete first-in-human trials.   Xpress Pharmaceutics allows Catalent to work alongside innovator and clinical research organizations (CRO), and provide formulated clinical tri...